School of Chemistry, National University of Ireland, Galway, Ireland.
Department of Chemistry, Faculty of Science, El-Menoufia University, Shebin El-Kom, Egypt.
Sci Rep. 2016 Jul 11;6:29367. doi: 10.1038/srep29367.
The use of Pt(IV) complexes as pro-drugs that are activated by intracellular reduction is a widely investigated approach to overcome the limitations of Pt(II) anticancer agents. A series of ten mono- and bis-carboxylated Pt(IV) complexes with axial indole-3-acetic acid (IAA) and indole-3-propionic acid (IPA) ligands were synthesized and characterized by elemental analysis, ESI-MS, FT-IR, (1)H and (195)Pt NMR spectroscopy. Cellular uptake, DNA platination and cytotoxicity against a panel of human tumor cell lines were evaluated. All the complexes are able to overcome cisplatin-resistance and the most potent complex, cis,cis,trans-[Pt(NH3)2Cl2(IPA)(OH)] was on average three times more active than cisplatin. Mechanistic studies revealed that the trend in cytotoxicity of the Pt(IV) complexes is primarily consistent with their ability to accumulate into cancer cells and to increase intracellular basal reactive oxygen species levels, which in turn results in the loss of mitochondrial membrane potential and apoptosis induction. The role of the indole acid ligand as a redox modulator is discussed.
将 Pt(IV) 配合物作为通过细胞内还原激活的前药使用是克服 Pt(II) 抗癌剂局限性的广泛研究方法。合成了一系列十种单羧酸和双羧酸化的 Pt(IV) 配合物,带有轴向吲哚-3-乙酸(IAA)和吲哚-3-丙酸(IPA)配体,并通过元素分析、ESI-MS、FT-IR、(1)H 和(195)Pt NMR 光谱进行了表征。评估了它们对一系列人类肿瘤细胞系的细胞摄取、DNA 铂化和细胞毒性。所有配合物都能够克服顺铂耐药性,最有效的配合物 cis,cis,trans-[Pt(NH3)2Cl2(IPA)(OH)]的平均活性比顺铂高 3 倍。机制研究表明,Pt(IV) 配合物的细胞毒性趋势主要与其在癌细胞中积累的能力以及增加细胞内基础活性氧水平的能力一致,这反过来又导致线粒体膜电位丧失和凋亡诱导。讨论了吲哚酸配体作为氧化还原调节剂的作用。